« Back
Home /
Recombinant Human IGF-BP2

Recombinant Human IGF-BP2

Manufacturer	Cell Sciences
Category	Oncology Metabolism Diabetes Cholesterol & Lipid Metabolism Regulation of Appetite Peptides & Proteins Recombinant Proteins
Type	Proteins
Specific against	Human
Amount	20 ug
Host	Insect
Item no.	CS-CRI272B
Targets	IGFBP2
eClass 6.1	34160400
eClass 9.0	42020190
Available
Biological Activity	Determined by its ability to inhibit IGF-I induced proliferation of FDC-P1 cells.
Description	IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP2 is a cysteine-rich secreted protein produced by bone cells, and is most abundant in the brain. IGF-BP2 has been shown to inhibit IGF-II action in human breast and ovarian carcinoma cells. Recombinant human IGF-BP2 consistS of 289 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.
Formulation	Lyophilized without additives.
Molecular Weight	31.5 kDa
Reconstitution	Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.5 mg/ml. The solution can then be further diluted in other aqueous buffers.
Storage and Stability	Lyophilized protein is preferably stored at -20C for up to two years. After reconstitution, stable for up to 3 months when stored in working aliquots with a carrier protein at -20C. Avoid repeated freeze-thaw cycles.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.